newsfilter
← Latest News
Business Wire·

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced